Abstract 300P
Background
Cervical cancer is the leading cause of death among gynecological cancers and ranks seventh among all types of cancer affecting women in Vietnam, with about 15.7% of cases occurring in women under 40 years old. Post-operative radiation therapy can cause ovarian dysfunction and related complications even in patients who had the ovaries transposed. This study aims to evaluate the extent of radiation exposure to the transposed ovaries and its impact on ovarian function in cervical cancer patients at the Ho Chi Minh City Oncology Hospital, who have undergone ovary transposition and received adjuvant radiation therapy.
Methods
We studied retrospectively radiation dosages and ovarian functions in cervix cancer patients who had ovarian transposition at our hospital from Jan 2020 to Dec 2021. We included patients under 45 years who completed at least 6 months of radiation therapy, and collected data on their medical records and radiotherapy planning software. Ovarian function was evaluated by FSH and estradiol levels before and after treatment. We used Epidata and Stata software to analyze the data and tested correlations using t-test pairing, Fisher test, and Spearman correlation.
Results
A total of 22 patients were included in the study. The mean radiation dose to the ovaries was positively correlated with PTV, ovarian position, stage and radiation technique. Of the 15 patients whose ovarian function was investigated after radiotherapy, 5 patients (33.33%) preserved ovarian function. The function preserved groups had lower ovarian radiation dosage. Table: 300P
Mean ovarian dosage (Gy) +/- SD (n) | Range | p | |
StageIB2IB3IIA1IIIC1p | 6,14 +/- 6,5 (16)14,26 +/- 12,14 (12)11,21 +/- 10,65 (4)15,86 +/- 15,29 (8) | 0,854-190.946-35,8670,963-21,130,885-45,562 | p=0,21 |
Ovarian position:Inside pelvis outside pelvis | 20,63 +/- 11,92 (13)6,4 +/- 7,88 (27) | 3,532-42,560,85-29,57 | 0,008 |
FunctionPreservedNot preserved | 1,29 +/- 2,13 (5)20,54 +/- 11,23 (10) | 1,09 -3,24,231-42,562 | 0,001 |
Technique3D CRTIMRT | 6,46 +/- 9,89 (27)19,45 +/- 9,03 (13) | 42,58 -0,8535,87 -5,29 | 0,0001 |
Conclusions
Transposed ovary location and mean ovarian dose are important factors in determining ovarian function outcomes. 3D CRT was better than IMRT, possibly due to scatter doses and inadequate ovarian dose constraints during radiation therapy planning. Increasing sample size and establishing a consistent practice protocol could enhance the validity of this study.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Ho Chi Minh City University of Medicine and Pharmacy.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
193P - Impact of coronavirus disease 2019 on patients with unresectable hepatocellular carcinoma treated with atezolizumab/bevacizumab
Presenter: Hongjae Chon
Session: Poster Display
Resources:
Abstract
194P - Real-world outcomes of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus chemotherapy as first-line treatment in advanced gastric (G) or gastroesophageal junction (GEJ) cancer with PD-L1 CPS≤5
Presenter: Qi Xu
Session: Poster Display
Resources:
Abstract
195P - Ferroptosis signatures in pancreatic ductal adenocarcinomas and their role in patient survival: A translational unsupervised clustering analysis
Presenter: Quoc-Huy Trinh
Session: Poster Display
Resources:
Abstract
196P - Clinical significance of circulating CD8+ and CD4+ T cell proliferation in advanced gastric cancer receiving first-line chemotherapy
Presenter: In-Ho Kim
Session: Poster Display
Resources:
Abstract
197P - Treatment patterns and clinical outcomes of patients with unresectable advanced or metastatic (UAM) gastric/gastroesophageal junction adenocarcinoma (GA/GEJA) in China: A multicenter real-world study
Presenter: Yanqiao Zhang
Session: Poster Display
Resources:
Abstract
198P - Effectiveness of lenvatinib in patients with unresectable hepatocellular carcinoma: A multicenter observational study in Japan
Presenter: Namiki Izumi
Session: Poster Display
Resources:
Abstract
199P - Efficacy of endostar in combination with concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of esophagus: A randomized, open-label, phase II trial
Presenter: Yuexiao Qi
Session: Poster Display
Resources:
Abstract
200P - Prognosis of patients with hepatocellular carcinoma treated with transarterial chemoembolization: Development and validation of the ALFP score
Presenter: Baocuo Gong
Session: Poster Display
Resources:
Abstract
201P - A phase II study of serplulimab (a programmed death-1 inhibitor) with or without HLX04 (a bevacizumab biosimilar) for the treatment of advanced hepatocellular carcinoma
Presenter: Zhenggang Ren
Session: Poster Display
Resources:
Abstract
202P - Comparison of liver injury after transcatheter arterial chemoembolization and hepatic arterial infusion chemotherapy for intermediate and advanced hepatocellular carcinoma
Presenter: Yongru Chen
Session: Poster Display
Resources:
Abstract